Scleroderma (3^rd Ed., 3rd ed. 2024)
From Pathogenesis to Comprehensive Management

This fully-updated third edition of Scleroderma: From Pathogenesis to Comprehensive Managementbuilds upon the well-regarded approach in the previous editions to provide integrated, concise, and up-to-date synthesis of current concepts of pathogenesis and modern approaches to management of systemic sclerosis (scleroderma). With a multidisciplinary approach to comprehensive care, this book is easily accessible for health care professionals in many fields. Comprised of the authoritative work of international experts, the new edition includes extensive updated material reflecting major developments in the field. It presents a succinct and thoughtful synthesis of current pathomechanistic concepts, providing a valuable reference tool for basic and translational investigators working in the field.  Scleroderma: From Pathogenesis to Comprehensive Management serves as an essential, all-inclusive and fully up to date resource for rheumatologists, pulmonologists, cardiologists, gastroenterologists, nephrologists and all those involved in the care of scleroderma patients.

Preface

                Foreword

Section 1: Introduction 

1              Historical perspective of scleroderma

Section 2: Epidemiology, Genetics and Classification        

2              Epidemiology, Environmental and Infectious Risk Factors

3              Influence of ethnicity and sex bias in systemic sclerosis

4              Genetic Factors

5              Classification and Disease Subsets in Clinical Practice

6              Clustering and evolving concepts for subclassification

7              The Clinical Aspects of Autoantibodies

8              Systemic sclerosis overlap syndromes

9              Juvenile Localized and Systemic Scleroderma

10           Morphea (Localized scleroderma)

Section 3: The Biological Basis of Systemic Sclerosis         

11           Scleroderma Mimics

12           Introduction: The Etiopathogenesis of Systemic Sclerosis - an Integrated Overview

13           Pathology of Systemic Sclerosis

14           INFLAMMATION AND IMMUNITY IN SYSTEMIC SCLEROSIS

15           Autoantibodies as Markers and Possible Mediators of Scleroderma Pathogenesis

16           Mechanisms of Vascular Disease

17           Biomarkers in Systemic Sclerosis

18           Cellular and molecular mechanisms of fibrosis in systemic sclerosis

19           Overview of Animal Models

Section 4: Cardiovascular Manifestations and Management         

20           Overview of management and outcome assessment in systemic sclerosis

21           Raynaud’s Phenomenon, Digital Ulcers and Nailfold Capillaroscopy

22           Renal crisis and other renal manifestations

23           CARDIAC INVOLVEMENT: EVALUATION AND MANAGEMENT

Section 5: Pulmonary Manifestations and Management

24           Overview of lung involvement

25           Clinical assessment of ILD

26           Lung Imaging Perspective in Scleroderma

27           Treatment of  Interstitial  Lung Disease in systemic sclerosis

28           Pathogenesis of Pulmonary Arterial Hypertension

29           Clinical Assessment of Pulmonary Hypertension

30           "The management of pulmonary arterial hypertension

in the setting of systemic sclerosis"

Section 6: Gastrointestinal Manifestations and Management      

32           Upper Gastrointestinal Tract: Manifestations of Systemic Sclerosis

33           Lower Gastrointestinal Tract Involvement: Understanding the Interplay of Motility, the Microbiome and Nutrition

Section 7: Skin, Musculoskeletal and Other Complications             

34           Evaluation and Management of Skin Disease

35           Calcinosis

36           Tendons, Joints, and Bone

37           Skeletal Muscle Involvement

38           Cancer in Systemic Sclerosis

39           Overlooked Manifestations

40           PREGNANCY

Section 8: Management and Outcome Assessment          

42           MANAGEMENT OF PROGRESSIVE SKIN INVOLVEMENT IN DIFFUSE SCLERODERMA

43           Hematopoietic stem cell transplantation

44           Immune targeted therapies in SSc.

45           Physical and Occupational Therapy

46           Psychosocial Issues and Care for Patients with Systemic Sclerosis

Section 9: Case Studies: Approach to Complex Clinical Problems

47           Measuring Disease Activity and Outcomes in Clinical Trials

48           Evolving clinical trial design and innovative approaches

49           Drug Development and Regulatory Considerations for Systemic Sclerosis Therapies

50           Managing the Ischemic Finger in Scleroderma

51           Scleroderma Renal Crisis: a case study

52           Rapid diffuse skin disease with progressive joint contractures

53           Management of the Scleroderma Patient with Pulmonary Arterial Hypertension Failing Initial Therapy

54           Pseudo-obstruction with malabsorption and malnutrition

55           Progressive Interstitial Lung Disease Non-Responsive to Immunosuppressive Therapy

56           Body Image Distress in Scleroderma

57           Managing Complicated Digital Ulcers

58           LOWER LIMB ULCERATION

Yannick Allanore

Service de Rhumatologie A,

Universit. Paris Descartes, Hôpital Cochin

Paris, France.

John Varga

Department of Internal Medicine

University of Michigan

Ann Arbor, Michigan, USA

Christopher P. Denton

Centre for Rheumatology

The Royal Free Hospital

London, United Kingdom

Masataka Kuwana

Department of Allergy and Rheumatology

Nippon Medical School

Tokyo, Tokyo, Japan

Lorinda Chung

Stanford Medicine

Rheumatology

Redwood City

California, USA

Ami Shah

Clinical and Translational Research

Johns Hopkins Hospital

Baltimore, Maryland, USA

Fully updated third edition

Provides a concise synthesis of pathogenesis and modern approaches to management of systemic sclerosis

Presents an integrated multidisciplinary approach to comprehensive patient care